November 10, 2020
[Moscow – 10.11.2020] InSysBio, one of the world’s pioneers of Quantitative Systems Pharmacology (QSP) modeling, presents the new access mode to Immune Response Template (IRT) version 3. Now any modeler can experience or get acquainted with IRT via Demo access without the necessity to purchase the license.
Generally, IRT is an efficient and useful tool to boost and facilitate the development of QSP models in immunology and immuno-oncology therapeutic areas. By this point IRT has been expanded to a fully-fledged database that embraces a wide range of reactions and species. However, InSysBio constantly goes further in its software advancement.
Demo access to IRT version 3 provides the opportunity to fully utilize 5 schemes, 2 cell passports, 2 cytokine passports and 1 immunologic synapse: IDEC, Th17, CCL20, IL17, Th0:IDECa. All the functionality of IRT Navigator is also available within the Demo version.
The instruction to get demo access to IRT version 3:
*If you don’t have an account yet:
About Immune Response Template (IRT):
IRT is a Quantitative Systems Pharmacology (QSP) platform of immune system and tool for development of QSP and mechanistic models related to immune response.
IRT consist of IRT Database and IRT Navigator. The core of IRT Database is IRT Core Model, a QSP model of immune system. IRT Navigator is an application software providing intuitive interface to work with IRT Database. IRT is an innovative tool allowing users to select all or any reactions and species from IRT Core Model and download it. To get more information please, visit: irt.insysbio.com
About InSysBio
InSysBio is a Quantitative Systems Pharmacology (QSP) company located in Moscow, Russia (INSYSBIO LLC) and Edinburgh, UK (INSYSBIO UK LIMITED). InSysBio was founded in 2004 and has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of QSP modeling. InSysBio’s innovative QSP approach has already become a part of the drug development process implemented by our strategic partners: there are more than 120 completed projects in collaboration with leaders of pharmaceutical industry. For more information about InSysBio, its solutions and services, visit www.insysbio.com.
| ← | November 2019 | → | ||||
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
|
1
|
2
|
3
| ||||
|
4
|
5
|
6
|
7
|
8
|
9
|
10
|
|
11
|
12
|
13
|
14
|
15
|
16
|
17
|
|
18
1.
18 Nov 2019 19:58
Course “Modeling for systems biology and biomedicine” at the Faculty of Bioengineering and Bioinformatics
This year InSysBio CEO Dr Oleg Demin with expert modelers Tatiana Karelina and Evgeny Metelkin and modelers Dmitry Shchelokov, Svetlana Rubina and Veronika Musatova are giving the course “Modeling for systems biology and biomedicine” at the Faculty of Bioengineering and Bioinformatics, Lomonosov Moscow State University.
|
19
|
20
|
21
|
22
|
23
|
24
|
|
25
1.
25 Nov 2019 18:47
PK/RO simulator for anti-PD-1 mAbs
InSysBio, a pioneer in Quantitative Systems Pharmacology (QSP), modeling and simulation for drug development, announced the launch of application ‘PK/RO simulator for anti-PD-1 mAbs’. The application is based on the model allowing to predict pharmacokinetics and target binding in human for therapeutic antibodies against PD-1 receptor.
|
26
|
27
|
28
|
29
|
30
| |